Loading
Carboplatin is a platinum chemotherapy that crosslinks DNA; it is part of the standard pre-surgery regimen for triple-negative breast cancer.
Carboplatin is a platinum chemotherapy that forms intrastrand DNA crosslinks, blocking replication and triggering apoptosis in dividing cells. First approved in 1989 for ovarian cancer and generic since 2004, it is dosed by the Calvert formula to a target AUC of 5 to 6 every 3 weeks or AUC 1.5 to 2 weekly with paclitaxel. It causes less kidney damage than cisplatin but more myelosuppression, with thrombocytopenia dose-limiting and hypersensitivity after 6 or more cycles. In triple-negative breast cancer, adding carboplatin to neoadjuvant chemotherapy raised pathological complete response rates in BrighTNess and GeparSixto, and it is part of the KEYNOTE-522 backbone, where pembrolizumab plus chemotherapy achieved pCR of 64.8% versus 51.2%. For a newcomer: a workhorse chemotherapy that damages DNA and underpins many curative-intent regimens.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
DNA intrastrand crosslinks.
1.Carboplatin is aquated inside the cell to a reactive platinum species
Source: www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications. Doses are for orientation; the current label governs.
Given by infusion or injection in a clinic or hospital outpatient department, so it is a Part B drug: Medicare pays 80% after the Part B deductible and the patient owes 20% coinsurance, uncapped in Original Medicare unless a Medigap policy applies. HCPCS J9045. Generic; supply shortages in 2023 affected access more than coverage did.
Multi-source generic; covered under the medical benefit without prior authorisation in most plans, as part of standard regimens.
Sources: Medicare.gov: Chemotherapy · Medicare.gov: Prescription drugs (outpatient, Part B). Not medical or financial advice; verify with your plan.
Sources: NICE search: carboplatin. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
| Region | Year | Indication |
|---|---|---|
| US | 1989 | Ovarian cancer (now broad use) |
| Adverse event |
|---|
| Thrombocytopenia |
| Anaemia |
| Neutropenia |
| Nausea and vomiting |
| Hypersensitivity (after ≥6 cycles) |
| Peripheral neuropathy (with paclitaxel) |
Events listed without rates were not read from a primary source; see the label. Blank cells mean the figure was not sourced, not that it is zero.
Read for the class this product belongs to (carboplatin) unless the answer names the product. Population figures from the cohorts named, not a prediction for one person. Blank where no source gives a recovery figure.
| Country | Reimbursement | List price | Assistance |
|---|---|---|---|
| United Statesgeneric | Medicare Part B; generic | not disclosed | - |
| United Kingdomgeneric | NHS standard; generic | not disclosed | - |
List prices are manufacturer or Medicare figures where publicly disclosed; net prices after rebates are usually lower. Reimbursement changes; check the payer.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Retifanlimab with carboplatin-paclitaxel is the new first-line standard for advanced anal squamous cell carcinoma; approved in the United States in May 2025.
Platinum and immunotherapy are now consensus for early triple-negative disease; the open votes have moved to who can safely receive less.
Adjuvant treatment for lung cancer is now chosen by genotype. A resected ALK-positive tumour is treated with two years of a tablet instead of four cycles of platinum, which is a different life as well as a different outcome.
Comprehensive genomic profiling at diagnosis is now justified for unfavourable cancer of unknown primary, with a switch to a matched drug after induction chemotherapy when an actionable target is found.
Durvalumab-based chemo-immunotherapy is a third first-line option with RUBY and NRG-GY018, and durvalumab plus olaparib maintenance is approved for mismatch repair-proficient disease in some regions.
Adding chemotherapy to osimertinib delays progression. Whether it extends life, and whether the same benefit could be had by giving the chemotherapy later to the patients who need it, is what the overall survival analysis and the registry watch on this roadmap are for.
Perioperative immunotherapy is now standard for resectable lung cancer without a targetable driver. The updated overall survival hazard ratio of 0.89, with a confidence interval crossing one, is the honest state of the evidence on whether it cures more people.
The strongest signal that neoadjuvant immunotherapy makes stage III lung cancer operable as well as more often curable. Twenty-four percentage points more patients reaching surgery is a result that only a neoadjuvant design can produce.
Query for this drug: (TITLE:"Carboplatin" OR ABSTRACT:"Carboplatin") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Carboplatin, not a curated reading list.
Shares A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors, A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer, A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors, A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer.
Shares CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ov, Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2), A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients, A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor.
Shares Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers, Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors, A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients, A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor.
Shares A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors, A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors, A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer, A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC.
Shares A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer, SKB500 Combinations in Patients With Small Cell Lung Cancer, A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors, HR-NBL1/SIOPEN: busulfan-melphalan versus carboplatin-etoposide-melphalan high-dose chemotherapy for high-risk neuroblastoma.
Shares A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage, A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC, A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) P, A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer.
Shares Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC, A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC, A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Ther, Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and C.
Shares A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer, Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer, A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors, Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy.